CAR‑T or Bispecific Antibodies? Distinct Real‑World Toxicity Patterns of BCMA‑Directed Immunotherapies in Relapsed/Refractory Multiple Myeloma: A FAERS Analysis of 4, 524 Reports (ICBMT 2026) - Oct 8, 2026 - Abstract #PP05‑09; " FAERS reports from inception through 2026 involving idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, and elranatamab were identified. In this real‑world FAERS analysis, BCMA‑directed CAR‑T therapies demonstrated higher reporting frequencies of cytokine release syndrome and neurotoxicity, whereas BCMA‑directed bispecific antibodies were associated with more infectious adverse events. These findings highlight distinct toxicity profiles that should inform treatment selection, toxicity monitoring, and supportive care strategies in patients with relapsed/refractory multiple myeloma. Keywords: Multiple Myeloma, BCMA‑Directed Immunotherapy, Pharmacovigilance"
Bispecific • Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • ROR1
|